Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03306615 · ClinicalTrials.gov registry record · Phase 2

Peripheral Modulation of Muscle Stiffness and Spasticity

A Phase 2 study of Muscle Spasticity, sponsored by Johns Hopkins University.

Active
Registry status
Phase 2
Development phase
56
Enrollment target
1
Study location

NCT03306615 is a Phase 2 study of Muscle Spasticity that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 56 participants, below the 75-participant average among 8 other Muscle Spasticity trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03306615, a Phase 2 study of Muscle Spasticity, is active but no longer recruiting, sponsored by Johns Hopkins University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

This is a single-center, double-blind, randomized, placebo-controlled, sequential Phase II trial of human recombinant hyaluronidase injections in individuals with post-stroke upper limb muscle stiffness. The investigators will recruit 56 subjects, who will be randomized to receive either the intervention or normal saline injections (first injection), and then the intervention the participants did not receive first (second injection). All individuals will receive the treatment by the end of the study.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Hyaluronidase

Study Locations (1)

Maryland

  • Johns Hopkins School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2021-10-11
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT03306615

The ClinicalTrials.gov registry entry for NCT03306615 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 75-participant average among 8 other Muscle Spasticity trials with a reported enrollment target (25% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Muscle Spasticity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03306615 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03306615 about?

NCT03306615 is a clinical study titled "Peripheral Modulation of Muscle Stiffness and Spasticity". This is a single-center, double-blind, randomized, placebo-controlled, sequential Phase II trial of human recombinant hyaluronidase injections in individuals with post-stroke upper limb muscle stiffness. The investigators will recruit 56 subjects, who will be randomized to receive either the interve...

What is the current status of trial NCT03306615?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2021-10-11. Estimated completion is 2026-06-30.

What conditions does trial NCT03306615 study?

This clinical trial studies the following conditions: Muscle Spasticity.

What interventions are being tested in trial NCT03306615?

The interventions under investigation include: Placebo (DRUG), Hyaluronidase (DRUG).

Who is sponsoring clinical trial NCT03306615?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03306615 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Muscle Spasticity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.